Why it Matters
Procter & Gamble Co. (P&G) has engaged BGR Government Affairs LLC to bolster its lobbying efforts specifically focused on health issues. This marks a strategic expansion in P&G’s lobbying strategy, emphasizing the importance of healthcare policy expertise.
By the Numbers
P&G has consistently spent $1.6-$2.5 million annually on lobbying over the past years. Their new lobbying team includes four seasoned lobbyists from BGR: Sydney Lee Terry, Remy Leigh Brim Mason, Marvin B. Figueroa, and John W. Stone.
Why Now
P&G’s decision is in response to regulatory updates such as the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) and increasing regulations on “forever chemicals” like PFAS. These changes directly impact P&G’s consumer health products.
The Agenda
P&G aims to influence FDA processes and rules regarding cosmetics, healthcare products, and related FDA mandates. BGR’s expertise in pharmaceutical and health policy is pivotal here.
Competitive Landscape
Currently, there is no specific information about competitors’ lobbying efforts on the same issues P&G is targeting with BGR.
Between The Lines
The current regulatory environment is shifting due to MoCRA and other recent laws, impacting consumer products significantly. P&G’s focus includes navigating FDA regulations and potential changes in OTC drug pathways.
The Bottom Line
P&G’s partnership with BGR underscores the importance of specialized lobbying in health sectors amidst tightening regulations. This move reflects proactive positioning in a changing regulatory landscape.
A official site
Spot something wrong? Report an issue with this article